Rossari Biotech Limited Earnings Summary — Q3 FY2025

• Consolidated revenue grew 10.6% YoY to ₹5,127.3 million, showing continued top-line scale.
• Profitability faced pressure with PAT declining 7.8% YoY and 10.3% QoQ, reflecting margin compression.
• Total expenses rose significantly, driven by a 22.8% YoY increase in employee benefit expenses and higher depreciation.
• The company expanded its global footprint by incorporating 'Rossari International' in Saudi Arabia and acquiring Unistar Thai Co. Ltd.
• Standalone results showed stronger sequential growth in revenue (+9.6%) and PAT (+11.7%) compared to consolidated performance.
• Board approved shifting the registered office to 'Rossari House' in Vikhroli, effective February 2025.
• The company continues to operate as a single segment under Specialty Chemicals, maintaining its diversified platform strategy.

Management remains focused on the 'Rossari 2.0' strategy, aiming for premiumization and multi-segment cross-selling across Home, Personal Care, Textile, and Animal Health segments. Execution is centered on integrating recent acquisitions to drive long-term capital efficiency despite current margin moderation.

Deteriorating

While revenue growth remains positive, the significant QoQ and YoY decline in net profit and narrowing margins signal a struggle to pass on costs or maintain pricing power amid expansion.

The outlook is focused on global expansion into Middle Eastern and SE Asian markets. However, the company must stabilize its operating margins and improve return on equity, which has trended downwards following aggressive capital expenditure.